Biotech | March 09, 2022
Alvotech settles with AbbVie to secure US rights to Humira biosimilar
Alvotech expects AVT02 (adalimumab) will be marketed in the U.S., subject to regulatory approval, on July 1, 2023
Alvotech expects AVT02 (adalimumab) will be marketed in the U.S., subject to regulatory approval, on July 1, 2023
Price was the key driver for the period
Nystatin and Triamcinolone Acetonide ointment is indicated for the treatment of cutaneous candidiasis
Toyobo will start looking at ways to use the knowhow from DMC’s sophisticated fermentation process technologies to enhance the efficiency of making its bioproducts
Taisho Pharmaceutical will bring its experience and expertise in the research and development of therapeutic products to the collaboration.
Brinton Pharmaceuticals enters exclusive sales and distribution rights of Scholl foot care products including Krack cream
Large players are adequately capitalised to make bigger investments to adjust for the ongoing fundamental shift in market opportunities
Technology adoption helped the industry to sail through Covid-19 disruption as it understood the need to digitize, learn, and excel
First of three Amneal biosimilars expected for U.S. approval and launch in 2022
Pankaj Patel, Chairman, Zydus Lifesciences; Umang Vohra, CEO, Cipla; G V Prasad, Co-Chairman, Dr Reddy's; Nilesh Gupta, MD, Lupin and Dilip Shanghvi, MD, Sun Pharmaceuticals sharing their vision to outline the roadmap for the industry.
Subscribe To Our Newsletter & Stay Updated
